4//SEC Filing
Doyle Noah 4
Accession 0001209191-20-013620
CIK 0001460702other
Filed
Feb 26, 7:00 PM ET
Accepted
Feb 27, 9:00 PM ET
Size
9.6 KB
Accession
0001209191-20-013620
Insider Transaction Report
Form 4
Doyle Noah
Director
Transactions
- Exercise/Conversion
Common Stock
2020-02-25$0.15/sh+500,000$75,000→ 1,204,780 total(indirect: By Javelin Partners, L.P.) - Exercise/Conversion
Warrants (right to buy)
2020-02-25−500,000→ 0 total(indirect: By Javelin Partners, L.P.)Exercise: $0.15From: 2017-10-03Exp: 2022-10-03→ Common Stock (500,000 underlying)
Holdings
- 2,272
Common Stock
- 32,275(indirect: By LLC)
Common Stock
Footnotes (4)
- [F1]On March 23, 2018, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock (the "Stock Split"). All share numbers and warrant exercise prices in this Form 4 reflect the Stock Split.
- [F2]As the managing director of Javelin Partners, L.P., the Reporting Person may be deemed the beneficial owner of these securities. The Reporting Person expressly disclaims beneficial ownership over these securities except to the extent of his pecuniary interest therein.
- [F3]As the managing director of Javelin Venture Partners I SPV I, LLC, the Reporting Person may be deemed the beneficial owner of these securities. The Reporting Person expressly disclaims beneficial ownership over these securities except to the extent of his pecuniary interest therein.
- [F4]As a result of the Stock Split and dilutive issuances of securities after the issuance of the warrants, the exercise price was adjusted to $0.15 per share.
Documents
Issuer
RITTER PHARMACEUTICALS INC
CIK 0001460702
Entity typeother
Related Parties
1- filerCIK 0001631673
Filing Metadata
- Form type
- 4
- Filed
- Feb 26, 7:00 PM ET
- Accepted
- Feb 27, 9:00 PM ET
- Size
- 9.6 KB